scholarly journals Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile – area under curve (PAP-AUC)

2019 ◽  
Vol 95 (3) ◽  
pp. 114854 ◽  
Author(s):  
A.C.O. Silveira ◽  
J. Caierão ◽  
C.I. Silva ◽  
E.K. Anzai ◽  
J.A. McCulloch ◽  
...  
Keyword(s):  
Area Under Curve ◽  
Population Analyses ◽  
Profile Area

Efektivitas Hipoglikemik Fraksi Etil Asetat Ampas Tahu menggunakan Model Hewan Ikan Zebra (Danio rerio)

2020 ◽  
Vol 5 (1) ◽  
pp. 16-21
Author(s):  
Nina Herlina ◽  
Mulyati ◽  
Yulianita ◽  
Putri Ananda
Keyword(s):  
Danio Rerio ◽  
Area Under Curve

Ampas tahu mengandung isoflavon genistein dan daidzein yang diduga memiliki efek hipoglikemik. Penelitian ini bertujuan untuk menguji efek hipoglikemik fraksi etil asetat ampas tahu (FEAAT). Ekstraksi isoflavon ampas tahu dilakukan dengan metode refluks menggunakan etanol dan HCl, kemudian fraksinasi menggunakan etil asetat. Efek hipoglikemik FEAAT dibuktikan menggunakan ikan zebra sebagai hewan uji. Kelompok perlakuan terdiri dari kontrol negatif (akuades), FEAAT1 dan FEAAT2 dengan konsentrasi 3,75% dan 5% serta kontrol positif (metformin). Hiperglikemia diinduksi dengan perendaman menggunakan aloksan 0,05% selama 30 menit, glukosa 1% selama 30 menit. Selanjutnya dilakukan pemberian sampel uji selama 120 menit secara berurutan untuk menguji efek hipoglikemik dari sampel uji. Cuplikan darah diambil pada menit ke-0, 30, 60, 90, dan 120 untuk diuji kadar glukosa darah. Hasil uji menunjukkan bahwa terdapat perbedaan yang nyata pada luas Area Under Curve (AUC0-120) kontrol negatif dengan FEAAT2 dan metformin (p < 0,01). Sementara hasil nilai AUC0-120 FEAAT1 tidak berbeda nyata dengan kontrol negatif. FEAAT2 efektif sebagai agen hipoglikemik pada model hewan ikan zebra yang diinduksi hiperglikemik.

THE ASSOCIATION OF THE APOLIPOPROTEIN E4 ALLELE (RS 429358) WITH OVARIAN SEROUS ADENOCARCINOMA

2017 ◽  
Vol 63 (4) ◽  
pp. 627-631
Author(s):  
Tatyana Ivanova ◽  
Nataliya Sychenkova ◽  
Vera Khorokhorina ◽  
Nikolay Ryabchenko ◽  
Sergey Ivanov ◽  
...  
Keyword(s):  
Older Women ◽  
Odds Ratio ◽  
Area Under Curve ◽  
Reproductive Age ◽  
Prognostic Indicators ◽  
Separate Analysis ◽  
Women Of Reproductive Age ◽  
Serous Adenocarcinoma ◽  
Ovarian Serous Adenocarcinoma ◽  
E4 Allele

The distribution of APOE 4 allele (rs 429358, C) was analyzed in healthy women (N=454) and patients with ovarian serous adenocarcinoma (N=114) in order to identify genetic predisposition to the disease. We determined the prognostic indicators of the E4 allele as a marker: odds ratio (OR) and AUC (Area Under Curve) - an area under the ROC curve. It was shown that APOE 4 allele was significantly associated with ovarian serous adenocarcinoma (p = 0,003; 0R=1,94; AUC=0,55). The Е4 genotypes frequency was significantly increased among patients (p = 0.02; 0R=1,8). Separate analysis of the two age subgroups (over 46 years and younger) found that the chance of developing ovarian serous adenocarcinoma was significantly increased for older women (p = 0,006; OR = 2,24, AUC = 0,76). Possible associations of APOE 4 with the ovarian serous adenocarcinoma in women of reproductive age deserve further studying.

scholarly journals Prognostic value of non-invasive coronary artery flow velocity assessment in elderly patients

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
E Kalinina ◽  
A Zagatina ◽  
N Zhuravskaya ◽  
D Shmatov
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery ◽  
Elderly Patients ◽  
Flow Velocity ◽  
Coronary Arteries ◽  
Coronary Flow ◽  
Prognostic Value ◽  
Area Under Curve ◽  
Left Coronary Artery ◽  
Maximal Velocity

Abstract Funding Acknowledgements Type of funding sources: None. Background There is a high prevalence of coronary artery disease (CAD) in the elderly population. However, symptoms of CAD are often non-specific. Dyspnoe, non-anginal pains are among the main symptoms in older patients. Exercise tests are of limited feasibility in these patients, due to neuro-muscular weakness, physical deconditioning, and orthopaedic limitations. Pharmacological tests often are contraindicated in a substantial percentage of elderly patients. Some recent studies indicate using local flow acceleration during routine echocardiography has prognostic potential for coronary artery assessments without stress testing. The aim of the study was to define the prognostic value of coronary artery ultrasound assessment in patients ≥75 years old. Methods This is a prospective cohort study. Patients ≥ 75 years old who underwent routine echocardiography with additional scans for coronary arteries over a period of 24 months were included in the study. The study group consisted of 80 patients aged 75-90 years (56 women; mean age 79 ± 4). Initial exams were performed for other reasons, primarily for arterial hypertension. Fifteen patients had known CAD. Death, non-fatal myocardial infarction (MI), and revascularization were defined as major adverse cardiac events (MACE). All patients were followed up with at a median of 32 months. Results There were 34 patients with high local velocities in the left coronary artery. Eight deaths, two non-fatal myocardial infarctions occurred, and 13 revascularizations were performed. With a ROC analysis, a coronary flow velocity &gt;110 cm/s was the best predictor for risk of death (area under curve 0.84 [95% CI 0.74–0.92]; sensitivity 75%; specificity 88%). Only the maximal velocity in proximal left-sided coronary arteries was independently associated with death (HR 1.03, 95% CI 1.01; 1.05; p &lt; 0.002), or death/MI (HR 1.03, 95% CI 1.01; 1.04; p &lt; 0.0001). The cut-off value of 66 cm/s was a predictor of all MACE (area under curve 0.87 [95% CI 0.77–0.94]; sensitivity 80%; specificity 86%). Any causes of death or MI occurred more frequently in patients with velocities of &gt;66 cm/s (27% vs. 2%; p &lt; 0.002). The rates of MACE were 58.0% vs. 2%; p &lt; 0.0000001, respectively. Conclusion The analysis of coronary flow in the left coronary artery during echocardiography can be used as a predictor of outcomes in elderly patients. Maximal velocities in proximal left-sided coronary arteries is independently associated with further death or myocardial infarction.

scholarly journals Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis

Antioxidants ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1043
Author(s):  
Carmen Peña-Bautista ◽  
Lourdes Álvarez-Sánchez ◽  
Inés Ferrer ◽  
Marina López-Nogueroles ◽  
Antonio José Cañada-Martínez ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Area Under Curve ◽  
Disease Diagnosis ◽  
Csf Biomarkers ◽  
Preclinical Ad ◽  
Aging Populations ◽  
Advanced Stages ◽  
Preclinical Diagnosis ◽  
T Tau ◽  
And Oxidative Stress

Background: Alzheimer disease (AD) is an increasingly common neurodegenerative disease, especially in countries with aging populations. Its diagnosis is complex and is usually carried out in advanced stages of the disease. In addition, lipids and oxidative stress have been related to AD since the earliest stages. A diagnosis in the initial or preclinical stages of the disease could help in a more effective action of the treatments. Methods: Isoprostanoid biomarkers were determined in plasma samples from preclinical AD participants (n = 12) and healthy controls (n = 31) by chromatography and mass spectrometry (UPLC-MS/MS). Participants were accurately classified according to cerebrospinal fluid (CSF) biomarkers and neuropsychological examination. Results: Isoprostanoid levels did not show differences between groups. However, some of them correlated with CSF biomarkers (t-tau, p-tau) and with cognitive decline. In addition, a panel including 10 biomarkers showed an area under curve (AUC) of 0.96 (0.903–1) and a validation AUC of 0.90 in preclinical AD prediction. Conclusions: Plasma isoprostanoids could be useful biomarkers in preclinical diagnosis for AD. However, these results would require a further validation with an external cohort.

scholarly journals Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose

2021 ◽  
Vol 18 (13) ◽  
pp. 7139
Author(s):  
Yue Wu ◽  
Jieqiang Zhu ◽  
Peter Fu ◽  
Weida Tong ◽  
Huixiao Hong ◽  
...  
Keyword(s):  
Machine Learning ◽  
Autoimmune Diseases ◽  
Odds Ratio ◽  
Area Under Curve ◽  
Predictive Performance ◽  
Drug Induced ◽  
Drug Candidates ◽  
Daily Dose ◽  
Structural Alerts ◽  
Underlying Mechanisms

An effective approach for assessing a drug’s potential to induce autoimmune diseases (ADs) is needed in drug development. Here, we aim to develop a workflow to examine the association between structural alerts and drugs-induced ADs to improve toxicological prescreening tools. Considering reactive metabolite (RM) formation as a well-documented mechanism for drug-induced ADs, we investigated whether the presence of certain RM-related structural alerts was predictive for the risk of drug-induced AD. We constructed a database containing 171 RM-related structural alerts, generated a dataset of 407 AD- and non-AD-associated drugs, and performed statistical analysis. The nitrogen-containing benzene substituent alerts were found to be significantly associated with the risk of drug-induced ADs (odds ratio = 2.95, p = 0.0036). Furthermore, we developed a machine-learning-based predictive model by using daily dose and nitrogen-containing benzene substituent alerts as the top inputs and achieved the predictive performance of area under curve (AUC) of 70%. Additionally, we confirmed the reactivity of the nitrogen-containing benzene substituent aniline and related metabolites using quantum chemistry analysis and explored the underlying mechanisms. These identified structural alerts could be helpful in identifying drug candidates that carry a potential risk of drug-induced ADs to improve their safety profiles.

scholarly journals SAT0500 HOW THE ADULT CRISS WORKS IN PEDIATRIC jSSc PATIENTS - RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1206.2-1206
Author(s):  
J. Klotsche ◽  
I. Foeldvari ◽  
O. Kasapcopur ◽  
A. Adrovic ◽  
K. Torok ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Area Under Curve ◽  
Health Assessment ◽  
Organ Damage ◽  
Left Ventricular ◽  
Inception Cohort ◽  
Research Support ◽  
Predicted Probability ◽  
New Onset

Background:The Composite Response Index in Systemic Sclerosis (CRISS) was developed by Dinesh Khanna as a response measure in patients with adult systemic sclerosis. CRISS aims to capture the complexity of systemic sclerosis and to provide a sensitive measure for change in disease activity. The CRISS score is based on a two-step approach. First, significant disease worsening or new-onset organ damage is defined as non-responsiveness. In patients who did not fulfill the criteria of part one, a probability of improvement is calculated for each patient based the Rodnan Skin Score (mRSS), percent predicted forced vital capacity (FVC%), patient and physician global assessments (PGA), and the Health Assessment Questionnaire Disability Index (HAQ-DI). A probability of 0.6 or higher indicates improvement.Objectives:The objective of this study was to validate the CRISS in a prospectively followed cohort of patients with juvenile systemic sclerosis (jSSc).Methods:Data from the prospective international inception cohort for jSSc was used to validate the CRISS. Patients with an available 12-months follow-up were included in the analyses. Clinically improvement was defined by the anchor question about improvement (much better or little better versus almost the same, little worse or much worse) in patients overall health due to scleroderma since the last visit provided by the treating physician.Results:Forty seven jSSc patients were included in the analysis. 74.2% had diffuse subtype. The physician rated the disease as improved in 34 patients (72.3%) since the last visit. No patient had a renal crisis or new onset of left ventricular failure during the 12-months follow-up. Three patients (3.4%) each had a new onset or worsening of lung fibrosis and new onset of pulmonary arterial hypertension. In total, 6 patients resulted in a rating of not improved based on the CRISS in part I. The mRSSS, FVC%, CHAQ and PGA significantly improved during the 12-months follow-up in patients who were rated as improved. The predicted probability based on the CRISS algorithm resulted in an area under curve of 0.77 predicting the anchor question of improvement. In summary, 33 (70.0%) patients were correctly classified by the adult CRISS score resulting in an overall area under curve of 0.7.Conclusion:The CRISS score was evaluated in a pediatric jSSc cohort for the first time. It showed a good performance. However, it seems that the formula of part II of the CRISS score needs a calibration to pediatric jSSc patients.Disclosure of Interests:Jens Klotsche: None declared, Ivan Foeldvari Consultant of: Novartis, Ozgur Kasapcopur: None declared, Amra Adrovic: None declared, Kathryn Torok: None declared, Valda Stanevicha: None declared, Jordi Anton Grant/research support from: grants from Pfizer, abbvie, Novartis, Sobi. Gebro, Roche, Novimmune, Sanofi, Lilly, Amgen, Grant/research support from: Pfizer, abbvie, Novartis, Sobi. Gebro, Roche, Novimmune, Sanofi, Lilly, Amgen, Consultant of: Novartis, Sobi, Pfizer, abbvie, Consultant of: Novartis, Sobi, Pfizer, abbvie, Speakers bureau: abbvie, Pfizer, Roche, Novartis, Sobi, Gebro, Speakers bureau: abbvie, Pfizer, Roche, Novartis, Sobi, Gebro, edoardo marrani: None declared, Maria T. Terreri: None declared, Flávio R. Sztajnbok: None declared, Cristina Battagliotti: None declared, Lillemor Berntson Consultant of: paid by Abbvie as a consultant, Speakers bureau: paid by Abbvie for giving speaches about JIA, Despina Eleftheriou: None declared, Gerd Horneff Grant/research support from: AbbVie, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Speakers bureau: AbbVie, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Farzana Nuruzzaman: None declared, Nicola Helmus: None declared

scholarly journals Role of postoperative radiotherapy in pT3N0 rectal cancer: A risk‐stratification system based on population analyses

2019 ◽  
Vol 8 (3) ◽  
pp. 1024-1033 ◽  
Author(s):  
Yun‐xia Huang ◽  
Yan‐zong Lin ◽  
Jin‐luan Li ◽  
Xue‐qing Zhang ◽  
Li‐rui Tang ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Risk Stratification ◽  
Postoperative Radiotherapy ◽  
Population Analyses ◽  
Stratification System ◽  
Risk Stratification System

scholarly journals Estimation of Tadalafil Using Derivative Spectrophotometry in Bulk Material and in Pharmaceutical Formulation

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Zamir G. Khan ◽  
Amod S. Patil ◽  
Atul A. Shirkhedkar
Keyword(s):  
Wavelength Range ◽  
Area Under Curve ◽  
Pharmaceutical Formulation ◽  
Second Order ◽  
Order Derivative ◽  
Uv Spectrophotometry ◽  
First Order ◽  
Beer's Law ◽  
Beer’S Law ◽  
Derivative Uv Spectrophotometry

Four simple, rapid, accurate, precise, reliable, and economical UV-spectrophotometric methods have been proposed for the determination of tadalafil in bulk and in pharmaceutical formulation. “Method A” is first order derivative UV spectrophotometry using amplitude, “method B” is first order derivative UV spectrophotometry using area under curve technique, “method C” is second order derivative UV spectrophotometry using amplitude, and “method D” is second order derivative UV spectrophotometry using area under curve technique. The developed methods have shown best results in terms of linearity, accuracy, precision, and LOD and LOQ for bulk drug and marketed formulation as well. In N,N-dimethylformamide, tadalafil showed maximum absorbance at 284 nm. For “method A” amplitude was recorded at 297 nm while for “method B” area under curve was integrated in the wavelength range of 290.60–304.40 nm. For “method C” amplitude was measured at 284 nm while for “method D” area under curve was selected in the wavelength range of 280.80–286.20 nm. For methods A and B, tadalafil obeyed Lambert-Beer’s law in the range of 05–50 μg/mL while for “methods C and D”, tadalafil obeyed Lambert-Beer’s law in the range of 20–70 μg/mL, and-for “methods A, B, C, and D” the correlation coefficients were found to be > than 0.999.

scholarly journals Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation

2015 ◽  
Vol 53 (11) ◽  
pp. 3543-3546 ◽  
Author(s):  
Riad Khatib ◽  
Kathleen Riederer ◽  
Mamta Sharma ◽  
Stephen Shemes ◽  
Sugantha P. Iyer ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Gold Standard ◽  
Population Analysis ◽  
Area Under The Curve ◽  
Brain Heart Infusion ◽  
Roc Curves ◽  
Clinical Samples ◽  
Content Type ◽  
Interpretation Criteria ◽  
Profile Area

BHI agars supplemented with vancomycin 4 (BHI-V4) and 3 (BHI-V3) mg/liter have been proposed for screening vancomycin intermediately susceptibleStaphylococcus aureus(VISA) and heteroresistant (hVISA) phenotypes, respectively, but growth interpretation criteria have not been established. We reviewed the growth results (CFU) during population analysis profile-area under the curve (PAP-AUC) of consecutive methicillin-resistantStaphylococcus aureus(MRSA) blood isolates, which were saved intermittently between 1996 and 2012. CFU counts on BHI-V4 and BHI-V3 plates were stratified according to PAP-AUC interpretive criteria: <0.90 (susceptible [S-MRSA]), 0.90 to 1.3 (hVISA), and >1.3 (VISA). CFU cutoffs that best predict VISA and hVISA were determined with the use of receiver operating characteristic (ROC) curves. Mu3, Mu50, and methicillin-susceptibleS. aureus(MSSA) controls were included. We also prospectively evaluated manufacturer-made BHI-V3/BHI-V4 biplates for screening of 2010-2012 isolates. The PAP-AUC of 616 clinical samples was consistent with S-MRSA, hVISA, and VISA in 550 (89.3%), 48 (7.8%), and 18 (2.9%) instances, respectively. For VISA screening on BHI-V4, a cutoff of 2 CFU/droplet provided 100% sensitivity and 97.7% specificity. To distinguish VISA from hVISA, a cutoff of 16 CFU provided 83.3% sensitivity and 94.7% specificity; the specificity was lowered to 89.5% with a 12-CFU cutoff. For detecting hVISA/VISA on BHI-V3, a 2-CFU/droplet cutoff provided 98.5% sensitivity and 93.8% specificity. These results suggest that 2-CFU/droplet cutoffs on BHI-V4 and BHI-V3 best approximate VISA and hVISA gold standard confirmation, respectively, with minimal overlap in samples with borderline PAP-AUC. Simultaneous screening for VISA/hVISA on manufacturer-made BHI-V4/BHI-V3 biplates is easy to standardize and may reduce the requirement for PAP-AUC confirmation.

Sign in / Sign up

Export Citation Format

Share Document